20 January 2006

I find it very interesting that Guidant stayed with J&J's offer even though Boston Scientific's offer was fiscally superior to their shareholders. Although, there is something to be said about the longterm worth about taking the last 13 months planning on how to merger the 2 companies. Still, I'm curious to see what Guidant's shareholders say during their vote later this month.